Morgan Stanley maintains Hims & Hers Health at Equal-Weight, lowers price target to $25 from $28
Morgan Stanley kept Hims & Hers Health at Equal-Weight, cutting its price target to $25 from $28, a 10.7% reduction. This implies a 9.0% upside from the Nov 9 close of $22.94, according to the bank.
How this was made
The 30-second read
Why it matters
The downgrade suggests weaker growth prospects, which could trigger short interest or sell pressure.
Market read
Analyst target revisions are a common catalyst for short-term price moves in the stock.
What to watch
Potential upcoming product launches or partnership announcements could offset the downgrade.
Background
Morgan Stanley's target change reflects its revised earnings expectations for Hims & Hers Health.
Ticker impact
Morgan Stanley lowered its price target for Hims & Hers Health to $25 from $28, indicating a fresh analyst downgrade.
likely downward pressure as investors price in the lower target
The new target is 10.7% lower than the previous one, suggesting reduced upside expectations.
Market effects
May affect other telehealth stocks as analysts reassess sector outlook.
Limited to US markets where HIMS trades.
Low global impact.
Counterpoint
Some investors may view the lower target as a buying opportunity if they believe the market overreacted.
Key entities
- AnalystMorgan Stanley
Equity research firm providing the price target update.
- CompanyHims & Hers Health
Telehealth provider whose stock is affected.
